SCHEMBL449665

SCHEMBL449665

N[C@H](C(=O)O)c1ccc(O)c(O)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 11/20 0.70
KDM4E B2RXH2 10/20 0.70
HSD17B10 Q99714 8/20 0.70
ALDH1A1 P00352 4/20 0.70
HPGD P15428 4/20 0.70
KMT2A Q03164 4/20 0.70
GRM1 Q13255 3/20 0.70
MEN1 O00255 3/20 0.70
CYP2C9 P11712 3/20 0.70
GRM2 Q14416 2/20 0.70
CYP2C19 P33261 2/20 0.70
BLM P54132 4/20 0.65
LMNA P02545 4/20 0.65
PTGS1 P23219 2/20 0.65
NR1I2 O75469 1/20 0.65
ADRA1A P35348 1/20 0.65
SLC6A2 P23975 2/20 0.58
DRD3 P35462 2/20 0.58
CYP2D6 P10635 1/20 0.58
GRM8 O00222 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10723439 1.00 TDP1 (0.70) TDP1KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL3478437 1.00 TDP1 (0.70) TDP1KDM4EHSD17B10ALDH1A1HPGD
Bromide SCHEMBL11670638 0.98 TDP1 (0.68) TDP1KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL10721569 0.83 TDP1 (0.55) TDP1KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL11926758 0.83 TDP1 (0.55) TDP1KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL12648648 0.82 HSD17B10 (1.00) TDP1KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL20522819 0.82 HSD17B10 (0.64) TDP1KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL20693801 0.82 HSD17B10 (0.64) TDP1KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL20522818 0.82 HSD17B10 (0.64) TDP1KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL11396129 0.82 HSD17B10 (0.64) TDP1KDM4EHSD17B10ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240408041-A1 COMPOSITIONS AND METHODS FOR TREATING CANNABINOID HYPEREMESIS SYNDROME HABBOUSHE JOSEPH (US) 2024-12-12 US claimed
EP-4237427-A1 ANTIBACTERIAL CYCLOPEPTIDES TARGETING ACINETOBACTER AND OTHER GRAM-NEGATIVE PATHOGENS University of Utah Research Foundation (US) 2023-09-06 EP claimed
CN-116670151-A Antibacterial cyclic peptides targeting acinetobacter and other gram negative pathogens 犹他大学研究基金会 2023-08-29 CN claimed
WO-2022094273-A1 ANTIBACTERIAL CYCLOPEPTIDES TARGETING ACINETOBACTER AND OTHER GRAM-NEGATIVE PATHOGENS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2022-05-05 WO claimed
WO-2021140526-A1 MUTANT PENICILLIN G ACYLASES OF ACHROMOBACTER CCM4824 FERMENTA BIOTECH LIMITED (IN) 2021-07-15 WO claimed
CN-107523219-B Chemical Mechanical Polishing (CMP) of cobalt-containing substrates 弗萨姆材料美国有限责任公司 2020-12-29 CN claimed
US-10745589-B2 Chemical mechanical polishing (CMP) of cobalt-containing substrate VERSUM MATERIALS US, LLC (US) 2020-08-18 US claimed
US-20200061155-A1 COMPOSITIONS AND METHODS FOR TREATING LYNX2 DISORDERS OPHIDION INC. 2020-02-27 US claimed
US-20190172720-A1 Chemical Mechanical Polishing (CMP) of Cobalt-Containing Substrate VERSUM MATERIALS US, LLC (US) 2019-06-06 US claimed
EP-3257910-B1 CHEMICAL MECHANICAL POLISHING (CMP) COMPOSITION, METHOD AND SYSTEM FOR COBALT-CONTAINING SUBSTRATE VERSUM MAT US LLC (US) 2019-03-27 EP claimed
EP-2604697-B1 Triprenyl phenol compounds, process for their production and use as thrombolysis enhancer UNIV TOKYO AGRICULTURE & TECHNOLOGY TLO CO LTD (JP) 2015-07-01 EP claimed
EP-2344151-A2 TREATMENT AND/OR PREVENTION OF INNER EAR CONDITIONS BY MODULATION OF A METABOTROPIC GLUTAMATE RECEPTOR HOUSE EAR INSTITUTE (US) 2011-07-20 EP claimed
WO-2010048095-A2 TREATMENT AND/OR PREVENTION OF INNER EAR CONDITIONS BY MODULATION OF A METABOTROPIC GLUTAMATE RECEPTOR HOUSE EAR INSTITUTE (US) 2010-04-29 WO claimed
US-7309719-B1 Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid WARNER LAMBERT COMPANY, LLC (US) 2007-12-18 US claimed
EP-1077692-B1 AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME WARNER LAMBERT CO (US) 2004-07-28 EP claimed
EP-0848064-B1 New antibiotic, Feglymycine, process for its preparation and use of the same HOECHST AG (DE) 2001-11-14 EP claimed
EP-1077692-A1 AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME Warner-Lambert Company LLC (US) 2001-02-28 EP claimed
WO-1999059573-A9 STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME WARNER LAMBERT CO (US) 2000-05-04 WO claimed
WO-1999059573-A1 STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME WARNER-LAMBERT COMPANY (US) 1999-11-25 WO claimed
EP-0164026-A1 Process for the preparation of optically active glycine derivatives BEECHAM GROUP PLC (GB) 1985-12-11 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240408041-A1 COMPOSITIONS AND METHODS FOR TREATING CANNABINOID HYPEREMESIS SYNDROME CNR2, TRPV1, CNR1 TDP1 2408/4885KDM4E 3214/4885HSD17B10 3191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.